Construction of MPEG-PCL Nanomicelle Ocular Drug Delivery Vector and Its Application in the Treatment of Hypertensive Fundus Disease

With the continuous development of society and the continuous development of technology, people's living standards have gradually improved, and the development of new things has gradually entered a new agenda. Alcoholism has gradually taken over most people's lives. Excessive drinking can lead to excessive alcohol content in the body, which is harmful to the liver. The stomach and other organs are affected, and the formation of high blood pressure is directly related to excessive drinking. And hypertensive patients are prone to have some adverse reactions and cause other more serious diseases. Hypertensive ocular fundus disease is one of its complications. Hypertensive ophthalmopathy is caused by abnormal changes in the retina, which can be very harmful. Patients with low rates and blindness can cause vision loss. Such diseases must be treated in time to allow patients to get rid of the troubles of the disease as soon as possible and restore their quality of life. In the treatment of hypertensive fundus disease, low-intensity laser radiation combined with nanomicelle ocular drug delivery carrier treatment has achieved a relatively ideal treatment effect. This article adopts the comparative treatment method and selects 120 patients with hypertensive ocular fundus disease admitted to X Hospital from 2018 to 2020 and evenly distributes them into the experimental group and the control group for comparative treatment experiments. Conclusions are obtained based on the analysis of treatment data. Related factors analyzed include age, gender, whether retinal laser photocoagulation has been performed before, and whether anti-VEGF treatment has been performed before surgery. The experimental results proved that there was no difference in the overall quality of life between the two groups before the treatment and at the end of the first course of treatment (P > 0.05), and the overall quality of life of the experimental group was higher than that of the control group until the end of the second course of treatment (P < 0.05). Hypertensive fundus disease is very harmful. If it is not treated in time, it will cause blindness in patients. In the treatment of hypertensive fundus disease, the use of low-intensity laser irradiation combined with MPEG-PCL nanomicelle therapy is beneficial to the recovery of vision and blood flow. The change index can guarantee the safety of treatment at the same time, which is worthy of clinical promotion.